투자정보

투명한 정보 공개와 시장과 소통하는 노력으로
주주님들과 함께 성장해 나가겠습니다.

HanAll BioPharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion

등록일|2018-08-14

첨부파일
HanAll BioPharma (CEO Park Seung-kook and CEO Yoon Jae-chun) announced on the 14th that it recorded consolidated sales of KRW 22.5 billion, operating profit of KRW 1.6 billion, and net profit of KRW 2.7 billion in the second quarter of this year. Sales grew by 9.4% YoY and operating profit and net profit increased by 526.1% and 443.6%, respectively.

Sales and operating profit for the first half of this year were KRW 44.6 billion and KRW 1.9 billion, respectively. Sales grew by 12.3% YoY and operating profit began its turnaround. Net profit for the quarter was KRW 3.4 billion, up 4068.3% from the same period last year.

HanAll BioPharma officials said, “Compared with the same period last year, sales and profitability improved due to increased profits from the export of HL161 technology and increased sales of pharmaceuticals.” “It will be a company that generates steady profits by drug sales growth and efficient management of costs through the sales synergies with Daewoong Pharmaceutical,” he added.

On the other hand, HanAll BioPharma has completed phase 2 clinical trial of HL036, a bio drug candidate for treatment of dry eye syndrome in 2Q in the United States. A total of 150 patients underwent clinical trials, and the results of topline were released in May. In the clinical trials, changes of ICSS (Inferior Corneal Staining Score) to observe the degree of corneal damage before and after exposure to the dry environment and ODS (Ocular Discomfort Score) to investigate subjective discomfort of eyes in patients for 8 weeks by dropping HL036 twice a day. As a result, ICSS change was significantly improved compared with placebo from 4 weeks after the administration of HL036, and ODS was significantly improved compared with placebo from 1 week after administration, verifying the excellent effectiveness and showing the strength of rapid onset of efficacy compared to its competitors.